India Pesticides Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/n9uqswxguyvgh476sxev7ypl.pdf

Key Takeaways


The China Overhang & Margin Mechanics

D.K. Jain: "We were earlier thinking that this is the lowest price, but because of increased supply from China, the prices have reduced in the last 3 months. So, we are still carrying the high cost inventory bought in fourth quarter of FY-23."

Revenue Growth & Product Engine

D.K. Jain: "Japanese team is very excited. We have got some synergies with this product. ... Recently delegate of 5 Japanese people, had come exclusively for IPL. They came from Tokyo and visited us and they went back." [15–16]

Capacity Expansion & the FY25 Revenue Path

D.K. Jain: "The capacity utilization, what we are doing even today is reasonably well. We are having capacity utilization of about 70% to 75%, which we feel in agrochemical industry is quite reasonable."

Regulatory & Competitive Position

D.K. Jain: "No, I don't think there is any uncertainty or certainty about that because recently, they have done thorough evaluation. And after that, they have given this decision. So we feel that it should be valid for at least coming 10 years."

R&D & Specialty Chemicals Pipeline


Demand & the Monsoon Wildcard

A.S. Agarwal: "As on today, we don't take this as any problem. Yes. There was less infestation last year, but as on today, we are quite hopeful."

Guidance & Commitments

CommitmentSpecificsTimeline
High-cost inventory flush-outUse Q4 FY23 high-cost inventory in productionQ1 and half of Q2 FY24
Gross margin recoveryMargins to improve after current ~46% levelAfter 1–2 quarters (H2 FY24)
China price stabilizationDownward trend of Chinese technical prices to stabilize1–2 quarters
Existing-site capex completionINR 50 crores capex (dedicated blocks + utilities)By November/December FY24
U.S. thiocarbamate first saleFirst commercial sale; ~INR 15 crores first-year salesAugust FY24
Hamirpur plant startFirst plant operations commenceQ4 FY24
New product revenue (FY23 cohort)INR 175 crores turnoverFY24
New product revenue (FY23 cohort)More than INR 200 crores turnoverFY25
Total revenue from current capexINR 1,200 crores (at current prices, 70–75% utilization)FY25 maximum
Asset turnover recoveryReach ~2.25 to 2.5xOnce all plants stabilized and at optimum utilization
EBITDA margins at INR 1,200 crores revenueAt least maintain present marginsFY25 (too early for precise forecast)

Key Metrics

MetricQ4 FY23
Total revenue₹201 cr, +10% YoY
FY23 total revenue₹898 cr, +23.2% YoY
EBITDA₹45 cr, margin 22.4%
FY23 EBITDA₹210 cr, margin 23.4%
Net profit₹30 cr, PAT margin 14.9%
FY23 net profit₹143 cr, PAT margin 15.9%
Export revenue FY23₹480 cr, +45% YoY
Domestic revenue FY23₹402 cr, +6% YoY
Technical revenue FY23₹704 cr
Formulation revenue FY23₹178 cr
Gross margin~46% currently
New products contribution FY23~₹120 cr
New products expected turnover FY24₹175 cr
Installed technical capacity24,000 MT, +2,500 MT during FY23
Capacity utilization70% to 75%
Capex invested in FY23₹68 cr for Sandila plant expansion
Planned capex FY24₹50 cr at Sandila, ₹60 cr at Shalvis Specialities
Closing inventory March FY23~₹225 cr, vs ₹140 cr last year
R&D expenses FY23~₹12 cr, ~1.25% of revenue (excluding manpower)
Dividend FY23₹0.75 per equity share on face value of ₹1
Thiocarbamate US registration potential~₹50 cr total, ~₹15 cr expected in first year
US exports as percentage of turnover~3%, ~₹30 cr currently
Peak revenue potential from existing capex₹1,100–1,200 cr (per an analyst's math)